Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia with Lewy bodies (DLB) or idiopathic Parkinson's disease and to differentiate them from Alzheimer's disease (AD) and control subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dementia with Lewy Bodies | Other |
| |
| Parkinson's disease | Other |
| |
| Healthy Elderly Volunteers | Other |
| |
| Alzheimer's Disease | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 18F-AV-133 | Drug | 185 MBq |
|
| Measure | Description | Time Frame |
|---|---|---|
| 18F-AV-133 striatal to occipital standard uptake value ratio | The ratio of tracer activity in striatal target areas of interest relative to the occipital cortex reference region | Four Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| 18F-AV-45 cortical to cerebellar standard uptake value ratio | The ratio of tracer activity in cortical target areas of interest relative to the cerebellum reference region | Four Weeks |
Not provided
Inclusion Criteria DLB:
Inclusion Criteria AD:
Inclusion Criteria PD:
Male or female > 50 years of age
Have probable PD according to the following criteria (Gelb et al., 1999):
A diagnosis of PD made within the 4 years prior to enrollment
Normal subjects:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chief Medical Officer | Avid Radiopharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Sun City | Arizona | United States | |||
| Research Site |
Not provided
| ID | Term |
|---|---|
| D020961 | Lewy Body Disease |
| D000544 | Alzheimer Disease |
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C549477 | florbenazine F 18 |
| C545186 | florbetapir |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 18F-AV-45 | Drug | 185-370 MBq |
|
| Philadelphia |
| Pennsylvania |
| United States |
| D009422 | Nervous System Diseases |
| D003704 | Dementia |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D024801 | Tauopathies |